The carbazole CBL0137 (1) is a lead for
drug development
against human African trypanosomiasis (HAT), a disease caused by Trypanosoma brucei. To advance 1 as
a candidate drug, we synthesized new analogs that were evaluated for
the physicochemical properties, antitrypanosome potency, selectivity
against human cells, metabolism in microsomes or hepatocytes, and
efflux ratios. Structure–activity/property analyses of analogs
revealed eight new compounds with higher or equivalent selectivity
indices (5j, 5t, 5v, 5w, 5y, 8d, 13i, and 22e). Based on the overall compound profiles, compounds 5v and 5w were selected for assessment in a mouse
model of HAT; while 5v demonstrated a lead-like profile
for HAT drug development, 5w showed a lack of efficacy.
Lessons from these studies will inform further optimization of carbazoles
for HAT and other indications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.